Literature DB >> 17060524

Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.

Elisabet I Nielsen1, Anders Viberg, Elisabeth Löwdin, Otto Cars, Mats O Karlsson, Marie Sandström.   

Abstract

Dosing of antibacterial agents is generally based on point estimates of the effect, even though bacteria exposed to antibiotics show complex kinetic behaviors. The use of the whole time course of the observed effects would be more advantageous. The aim of the present study was to develop a semimechanistic pharmacokinetic (PK)/pharmacodynamic (PD) model characterizing the events seen in a bacterial system when it is exposed to antibacterial agents with different mechanisms of action. Time-kill curve experiments were performed with a strain of Streptococcus pyogenes exposed to a wide range of concentrations of the following antibiotics: benzylpenicillin, cefuroxime, erythromycin, moxifloxacin, and vancomycin. Bacterial counts were monitored with frequent sampling during the experiment. A simultaneous fit of all data was accomplished. The degradation of the drugs was monitored and corrected for in the model, and a link model was used to account for an effect delay. In the final PK/PD model, the total bacterial population was divided into two subpopulations: one growing drug-susceptible population and one resting insusceptible population. The drug effect was included as an increase of the killing rate of bacteria in the susceptible state, according to a maximum-effect (E(max)) model. An internal model validation showed that the model was robust and had good predictability. In conclusion, for all drugs, the final PK/PD model successfully described bacterial growth and killing kinetics when the bacteria were exposed to different antibiotic concentrations. The semimechanistic model that was developed might, after further refinement, serve as a tool for the development of optimal dosing strategies for antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060524      PMCID: PMC1797646          DOI: 10.1128/AAC.00604-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models.

Authors:  Alasdair MacGowan; Karen Bowker
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

4.  Bacterial persistence as a phenotypic switch.

Authors:  Nathalie Q Balaban; Jack Merrin; Remy Chait; Lukasz Kowalik; Stanislas Leibler
Journal:  Science       Date:  2004-08-12       Impact factor: 47.728

Review 5.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

6.  Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.

Authors:  I Gustafsson; E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999.

Authors:  Ian A Critchley; Daniel F Sahm; Clyde Thornsberry; Renée S Blosser-Middleton; Mark E Jones; James A Karlowsky
Journal:  Diagn Microbiol Infect Dis       Date:  2002-02       Impact factor: 2.803

Review 8.  How predictive is PK/PD for antibacterial agents?

Authors:  Niels Frimodt-Møller
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

9.  Persister cells and tolerance to antimicrobials.

Authors:  Iris Keren; Niilo Kaldalu; Amy Spoering; Yipeng Wang; Kim Lewis
Journal:  FEMS Microbiol Lett       Date:  2004-01-15       Impact factor: 2.742

10.  Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein.

Authors:  Scott Marshall; Fiona Macintyre; Ian James; Michael Krams; Niclas E Jonsson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

View more
  58 in total

1.  Mathematical modeling to characterize the inoculum effect.

Authors:  Pratik Bhagunde; Kai-Tai Chang; Renu Singh; Vandana Singh; Kevin W Garey; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

2.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

5.  Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model.

Authors:  E D Pieterman; S van den Berg; A van der Meijden; E M Svensson; H I Bax; J E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

7.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

8.  Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.

Authors:  Wang Hengzhuang; Hong Wu; Oana Ciofu; Zhijun Song; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

9.  Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.

Authors:  Stephan Schmidt; Sreedharan Nair Sabarinath; April Barbour; Darren Abbanat; Prasarn Manitpisitkul; Sue Sha; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

10.  Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.

Authors:  Cornelia B Landersdorfer; Neang S Ly; Hongmei Xu; Brian T Tsuji; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.